Investor Presentaiton
Development capabilities in complex injectables
Complex injectable drug products
Long-acting Injectables using micro-
sphere technology
Key technologies involved
•
Sustained drug release
•
Reducing injection frequency
•
Polymeric microspheres
•
In-situ forming depots
.
•
Advanced in-vitro efficacy read-outs
Advanced polymer characterization
Kwality experience
Developed complex long-acting injectables:
Leuprolide depot injectable, Octreotide Acetate
injectable Suspension, Risperidone Long-Acting
injectable, Goserelin Acetate Depot injectable
•
Tissue targeting
•
Intracellular targeting
Liposomal Injectables
.
Increase exposure time
•
Drug solubilization and stabilization
Developed complex oncology injectables:
Daunorubicin Liposomal Injection and
Doxorubicin Liposomal Injection with stability
data of 24 months
•
Protein-based Injectables
•
Selectivity for specific protein targets
•
Higher potency and reduced toxicity than many
small molecules
Improved stability & control release
Developed complex protein based injectables:
Erythropoietin Injectable, Alteplase for Injection,
Darbepoetin injectable for intravenous and
subcutaneous
•
Solubility using freeze-drying
Lyophilized Injectables
•
Improved stability, solubility and stability
Developed complex Lyophilized products:
Paclitaxel injection suspension, Amphotericin B
inj., Caspofungin Acetate inj., Isoniazid inj.,
Micafungin inj., Rifampin inj., Tenoxicam inj.,
Suxamethonium inj.
8View entire presentation